What Are Aberrant Behaviours in Opioid Use?

Recognising problematic medication use patterns and what they mean for your insurance claims management.

Published: 4 April 2026

Introduction

Aberrant behaviour in opioid use refers to any pattern of medication use that falls outside expected therapeutic parameters. As an insurance claims manager, understanding aberrant behaviours is critical because they often signal that opioid therapy is not being used as intended, that the claimant may be at risk of medication misuse or addiction, or that the treatment agreement is not being followed.

Importantly, aberrant behaviour is not synonymous with addiction or criminal activity. It may reflect problematic medication use, but it may also reflect confusion, desperation from inadequate pain relief, or circumstances beyond the claimant's control. Your role is to identify these patterns, understand what they mean, and determine what response is appropriate.

Defining Aberrant Behaviour

Aberrant behaviour in opioid use is defined as any deviation from the agreed treatment plan that suggests the medication is not being used therapeutically. Common definitions in addiction medicine include use that is "inconsistent with medical supervision or treatment goals." This broad definition recognises that aberrant behaviour can take many forms.

Key elements of aberrant behaviour include:

• It falls outside the explicit treatment agreement between patient and provider
• It suggests the opioid is being used in ways other than prescribed (different route, different timing, different dose)
• It suggests diversion (the medication is not being used by the patient who it was prescribed to)
• It suggests multiple sources of opioids without coordination
• It raises concerns about addiction or medication misuse
• It indicates the patient is seeking opioids despite harms or lack of benefit

Common Types of Aberrant Behaviour

Doctor Shopping and Multiple-Prescriber Presentations

Doctor shopping occurs when a patient obtains opioid prescriptions from multiple prescribers without each prescriber knowing about the others. This is one of the most significant aberrant behaviours because it often indicates intentional medication seeking and creates overdose risk through duplicate therapy.

In Australia, detection of doctor shopping has improved dramatically with implementation of SafeScript (Victoria and other states) and QScript (Queensland). These real-time prescription monitoring (RTPM) systems flag when a patient fills opioid prescriptions at multiple prescribers or pharmacies within short timeframes.

What to do: Request SafeScript or QScript reports for any claimant on long-term opioids. If multiple-prescriber presentations are detected, contact the patient's primary prescriber immediately. The treatment agreement should explicitly prohibit obtaining opioids from other sources without disclosure. Multiple-prescriber presentations warrant documented discussion with the patient about the risks and either consolidation to a single prescriber or cessation of opioid therapy.

Early Refills and Running Out Early

When a claimant requests refills before the previous supply should be exhausted, this suggests either that more medication is being taken than prescribed or that medication is being diverted to others. Early refills are easily detected through pharmacy records or SafeScript reports.

Early refills might occur because the patient miscalculated, took extra doses during a period of high pain, or intentionally overused the medication. Occasionally, they reflect loss of medication due to theft or accident. Understanding the reason is important before determining how to respond.

What to do: When early refills are detected, contact the patient to understand why. If a legitimate reason exists (pain escalation, medication loss), document the reason and monitor closely for recurrence. If the explanation is implausible or early refills are recurring, this signals either medication overuse or diversion. Request the treating provider discuss the pattern with the patient and consider structured opioid treatment agreement with explicit limits on refill timing.

Lost or Stolen Prescriptions and Medications

While occasionally a prescription or medication is genuinely lost or stolen, repeated reports of loss should raise concern. Some claimants develop a pattern of reporting lost medications, receiving replacement prescriptions, and then the "lost" medication reappearing or being sold.

After the first incident, implement precautions such as requiring replacement prescriptions to be issued only under specific conditions (e.g., written request with supporting evidence, limited number of replacements per year).

What to do: For the first reported loss, provide one replacement. Document the incident. If a second loss is reported within 12 months, require written documentation of the loss and police report if theft. If multiple losses are reported, this warrants conversation with the treating provider and consideration of whether opioid therapy can continue safely. Prescribing guidelines generally allow only 1-2 lost medication replacements per year before medication refusal is appropriate.

Dose Escalation Without Clinical Rationale

When a patient repeatedly requests dose increases, or when medical records show doses being escalated without documented objective reason (such as pain score progression), this suggests medication-seeking behaviour. Some patients develop increasing tolerance or escalating pain that justifies dose increases; others request increases for other reasons.

Distinguishing appropriate dose increases from medication-seeking behaviour requires careful evaluation of pain and functional data. If pain is unchanged but doses escalate, or if pain is unchanged despite multiple dose increases, aberrant behaviour or treatment failure should be suspected.

What to do: Request that treating providers justify dose increases with specific pain and functional data. "Patient requests increase" without objective clinical reason is not adequate justification. If dose escalation continues without objective clinical basis, request independent medication review and consider dose stabilisation or reduction.

Concurrent Use of Other Sedating Substances

Using opioids alongside benzodiazepines, alcohol, or other sedating drugs creates serious overdose risk. This pattern may reflect the patient's attempt to enhance the effect of opioids, inadequate prescriber oversight (multiple providers not communicating), or the patient's difficulty stopping other substances despite opioid therapy.

Urine drug screening often detects these patterns. A positive screen for benzodiazepines when they were not prescribed, or positive alcohol metabolite findings, indicate concurrent substance use.

What to do: If concurrent benzodiazepine use is detected, the treatment agreement should have prohibited this. Contact the treating provider immediately. A documented plan for benzodiazepine taper or addiction medicine consultation should be implemented. If the pattern continues, opioid therapy may need to be discontinued because the overdose risk becomes unacceptable.

Positive Urine Drug Screening for Non-Prescribed Substances

Urine drug screening that reveals illicit drugs or non-prescribed medications suggests either that the patient is using substances outside the treatment plan or that the patient is diverting prescribed medications and obtaining others. This is a significant safety concern.

Be aware that some positive results may reflect false positives or cross-reactivity. Confirm unexpected positive results before acting, and provide opportunity for the patient to explain before assuming misconduct.

What to do: When positive drug screening is detected, discuss the result with the patient. Provide opportunity for them to explain (for example, "my partner's benzodiazepines showed up" or "I took ibuprofen that contained a banned substance"). If an explanation is provided and seems plausible, further testing may clarify. If positive results persist without adequate explanation, this indicates treatment plan non-compliance and warrants consultation with addiction medicine and likely discontinuation or restructuring of opioid therapy.

Negative Urine Drug Screening When Opioids Expected

If a patient who is prescribed opioids produces urine drug screening that does not detect opioids, this suggests the medication is not being taken (diversion, non-compliance, or sale to others). This pattern is sometimes called "missed positive" screening.

Non-detection might occur because the patient forgot to take the medication, took less than prescribed, or is diverting the medication. Understanding which is happening is important.

What to do: Discuss the finding with the patient. Ask directly whether they are taking the medication as prescribed and why it was not detected in their urine. If compliance is confirmed but opioids are not detected, request confirmatory testing. If non-detection is confirmed, this suggests either non-compliance (medication not being taken) or diversion (medication being sold or given to others). Both warrant discussion with the treating provider and reconsidering whether opioid therapy is appropriate.

Requests for Medications in Unusual Quantities or Intervals

Requests for unusually large quantities, requests for early dispensing, or requests for medications in unusual formulations may indicate medication misuse. For example, requesting extended-release opioids early in large quantities, or requesting crush-able formulations when modified-release is medically appropriate, may suggest misuse intent.

What to do: Question requests that seem inconsistent with the patient's treatment goals. Involve the pharmacist or treating provider in assessing whether the request is clinically appropriate. If not, deny the request and document the reason.

Aberrant Behaviour Classification and Response Framework

Distinguishing Aberrant Behaviour from Legitimate Pain Escalation

A single episode of requesting an early refill in a patient with documented pain escalation is different from a pattern of early refills in a patient with unchanged pain. Context matters, and your assessment should reflect this nuance.

Your Role in Responding to Aberrant Behaviour

Documentation

Every instance of suspected aberrant behaviour should be carefully documented with: what behaviour was detected, when it was detected, what data source revealed it, and what action was taken in response. This documentation protects you, supports clinical decision-making, and creates an audit trail if the behaviour escalates.

Communication

In most cases, you should involve the treating provider before taking significant action. Providers often have context about the patient that explains the behaviour or allows them to address it directly. However, if behaviour suggests imminent safety risk (for example, concurrent opioid and benzodiazepine use), immediate action may be warranted without waiting for provider response.

Non-Judgmental Approach

Frame discussions about aberrant behaviour in neutral, clinical language: "Our monitoring system detected multiple-prescriber presentations. Can you help me understand what's happening?" rather than accusatory language: "You've been doctor shopping." This approach is more likely to elicit cooperation and honest discussion.

Structured Response

Minor incidents warrant monitoring and education. Patterns warrant documented discussion and treatment agreement reinforcement. Serious incidents warrant independent assessment, possible addiction medicine involvement, and potentially opioid cessation.

Conclusion

Aberrant behaviour in opioid use is an important signal that something in the treatment plan may not be working. Whether it represents medication overuse, diversion, concurrent substance use, or inadequate pain control, it warrants investigation and response. By understanding common types of aberrant behaviour, classification systems for severity, and appropriate response strategies, you're positioned to identify concerning patterns early and intervene before situations escalate.

Remember that aberrant behaviour is not synonymous with addiction or intentional misconduct. However, it does signal that opioid therapy, as currently structured, may not be safe or appropriate for this patient. Your role is to identify these patterns objectively and implement evidence-based responses that protect your claimant while ensuring they receive appropriate pain management.